tranexamic acid has been researched along with Spinal Neoplasms in 5 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Spinal Neoplasms: New abnormal growth of tissue in the SPINE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary outcome was postoperative blood loss, and the secondary outcomes were postoperative PRC transfusion and complications." | 3.11 | Adjunctive Topical Tranexamic Acid for Blood Salvage Does Not Reduce Postoperative Blood Loss Compared with Placebo in Patients Who Undergo Palliative Decompressive Spinal Metastasis Surgery: A Randomized Controlled Trial. ( Atthakomol, P; Maethungkul, R; Murakami, H; Phanphaisarn, A; Phinyo, P; Sangsin, A, 2022) |
| "Patients suffered from acute spinal cord compression caused by spinal tumor manifestation (n = 5), empyema (n = 4), degenerative spinal stenosis (n = 1), hematoma (n = 1), and vertebral body fracture/dislocation (n = 2)." | 1.51 | Management of Spinal Emergencies in Patients on Direct Oral Anticoagulants. ( Beynon, C; Gumbinger, C; Olivares, A; Unterberg, AW; Younsi, A; Zweckberger, K, 2019) |
| "Tranexamic acid was used arbitrarily in 36 of them, while the other 47 did not receive TXA." | 1.51 | Blood loss and perioperative transfusions related to surgery for spinal tumors. Relevance of tranexamic acid. ( Damade, C; Foulongne, E; Gauthé, R; Gilard, V; Ould-Slimane, M; Tesson, G; Vigny, S, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maethungkul, R | 1 |
| Atthakomol, P | 1 |
| Phinyo, P | 1 |
| Phanphaisarn, A | 1 |
| Murakami, H | 1 |
| Sangsin, A | 1 |
| Beynon, C | 1 |
| Olivares, A | 1 |
| Gumbinger, C | 1 |
| Younsi, A | 1 |
| Zweckberger, K | 1 |
| Unterberg, AW | 1 |
| Damade, C | 1 |
| Tesson, G | 1 |
| Gilard, V | 1 |
| Vigny, S | 1 |
| Foulongne, E | 1 |
| Gauthé, R | 1 |
| Ould-Slimane, M | 1 |
| Bednar, DA | 1 |
| Bednar, VA | 1 |
| Chaudhary, A | 1 |
| Farrokhyar, F | 1 |
| Farroukhyar, F | 1 |
| Cravens, GT | 1 |
| Brown, MJ | 1 |
| Brown, DR | 1 |
| Wass, CT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Topical Tranexamic Acid in Total Hip Arthroplasty[NCT01866943] | Phase 2 | 41 participants (Actual) | Interventional | 2011-11-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Estimated Blood Loss defined as Pre Op Hgb mins the Post Op Day two Hgb. (NCT01866943)
Timeframe: Pre Op, Post Op Day 2
| Intervention | Hemoglobin (grams/deciliter) (Mean) |
|---|---|
| Baseline Population | 2.93 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 2 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 65.76 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 6 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 81.77 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: Preoperative
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 58.34 |
Measurement of the thigh at the half way point between the prominence of the greater trochanter and the lateral epicondyle of the femur. No data recorded at 2 weeks or 6 weeks for this study population. (NCT01866943)
Timeframe: Pre Op
| Intervention | centimeters (Mean) |
|---|---|
| Baseline Population | 52.99 |
1 trial available for tranexamic acid and Spinal Neoplasms
| Article | Year |
|---|---|
Adjunctive Topical Tranexamic Acid for Blood Salvage Does Not Reduce Postoperative Blood Loss Compared with Placebo in Patients Who Undergo Palliative Decompressive Spinal Metastasis Surgery: A Randomized Controlled Trial.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Hemorr | 2022 |
4 other studies available for tranexamic acid and Spinal Neoplasms
| Article | Year |
|---|---|
Management of Spinal Emergencies in Patients on Direct Oral Anticoagulants.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Blood Coagulation Factors; Bl | 2019 |
Blood loss and perioperative transfusions related to surgery for spinal tumors. Relevance of tranexamic acid.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Decompression, Surgic | 2019 |
Tranexamic acid for hemostasis in the surgical treatment of metastatic tumors of the spine.
Topics: Adult; Aged; Aged, 80 and over; Female; Hemostasis, Surgical; Humans; Male; Middle Aged; Retrospecti | 2006 |
Antifibrinolytic therapy use to mitigate blood loss during staged complex major spine surgery: Postoperative visual color changes after tranexamic acid administration.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Chordoma; Color Perception; Color Vision Defects; Hum | 2006 |